Deakin University
Browse

File(s) under permanent embargo

Psilocybin-assisted therapy for depression: How do we advance the field?

Version 2 2024-06-03, 21:05
Version 1 2020-02-12, 09:10
journal contribution
posted on 2024-06-03, 21:05 authored by SE Meikle, P Liknaitzky, SL Rossell, M Ross, N Strauss, N Thomas, G Murray, M Williams, DJ Castle
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment, including clarification of the profile of people most likely to benefit and those who might experience adverse effects, longer-term outcomes and the role of psychotherapeutic input alongside the drug itself. There are also opportunities to understand better, the neurobiology underpinning its effects.

History

Journal

Australian and New Zealand Journal of Psychiatry

Volume

54

Pagination

225-231

Location

London, Eng.

ISSN

0004-8674

eISSN

1440-1614

Language

eng

Publication classification

C2 Other contribution to refereed journal

Copyright notice

2019, Royal Australian and New Zealand College of Psychiatrists

Issue

3

Publisher

Sage Publications

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC